High Affinity Hiv T Cell Receptors
AssigneeAvidex Limited
InventorsBent Karsten Jakobsen, Yi Li, Steven Mark Dunn, Peter Eamon Molloy
Life of this patent
Estimating the term…
Abstract
The present invention provides TCRs having an affinity (KD) of less than or equal to 1 μM, and/or an off-rate (koff) of 1×10−3S−1 or slower, for the SLYNTVATL-HLA-A*0201 complex provided that when the said TCR is presented by cell and comprises SEQ ID NOS:1 and 2, the cell is not a native T cell. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting HIV infected cells presenting that complex.
Claims22
1-55. (canceled)
A T-cell receptor (TCR) having the property of binding to SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 and comprising at least one TCR α chain variable domain and/or at least one TCR β chain variable domain characterized in that said TCR has a KD for the said SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex of less than or equal to 1 μM and/or has an off-rate (koff) for the SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex of 1×10−3 S−1 or slower, provided that when the said TCR is presented by cell and comprises SEQ ID NOS:
- 1 and 2, the cell is not a native T cell.
An isolated nucleic acid encoding the alpha chain and/or the beta chain of a TCR having the property of binding to SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 and comprising at least one TCR α chain variable domain and/or at least one TCR β chain variable domain characterized in that said TCR has a KD for the said SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex of less than or equal to 1 μM and/or has an off-rate (koff) for the SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex of 1×10−3S−1 or slower, provided that when the said TCR is presented by cell and comprises SEQ ID NOS:1 and 2, the cell is not a native T cell.
Dependencies are inferred from the claim text.